Investment Analysts’ Recent Ratings Updates for DexCom (DXCM)

Several analysts have recently updated their ratings and price targets for DexCom (NASDAQ: DXCM):

• 3/4/2026 – DexCom was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 2/25/2026 – DexCom had its “buy” rating reaffirmed by BTIG Research. They now have a $85.00 price target on the stock.
• 2/18/2026 – DexCom was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 2/17/2026 – DexCom had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $80.00 price target on the stock, down from $82.00.
• 2/13/2026 – DexCom was given a new $87.00 price target by Robert W. Baird.
• 2/13/2026 – DexCom was given a new $95.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 2/13/2026 – DexCom had its “underweight” rating reaffirmed by Barclays PLC. They now have a $72.00 price target on the stock, up from $71.00.
• 2/13/2026 – DexCom had its price target lowered by Wells Fargo & Company from $93.00 to $85.00. They now have an “overweight” rating on the stock.
• 2/13/2026 – DexCom had its price target raised by Mizuho from $78.00 to $90.00. They now have an “outperform” rating on the stock.
• 2/13/2026 – DexCom had its “buy” rating reaffirmed by BTIG Research. They now have a $85.00 price target on the stock.
• 2/5/2026 – DexCom had its “overweight” rating reaffirmed by Piper Sandler.
• 2/4/2026 – DexCom was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 1/12/2026 – DexCom had its “overweight” rating reaffirmed by Morgan Stanley.
• 1/12/2026 – DexCom was downgraded by Barclays PLC from “equal weight” to “underweight”. They now have a $71.00 price target on the stock, down from $80.00.
• 1/9/2026 – DexCom had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $86.00 price target on the stock, up from $84.00.

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.